Business Context and Reporting Period
Pharming Group N.V. filed this Form 6-K on March 8, 2022, furnishing a notice that it would announce preliminary, unaudited full-year 2021 results for the year ended December 31, 2021, on March 17, 2022. The filing itself does not contain the 2021 financial results.
Pharming is a commercial-stage biopharmaceutical company focused on rare diseases and unmet medical needs. Its principal commercial product is RUCONEST, a recombinant human C1 esterase inhibitor approved for acute hereditary angioedema attacks and commercialized directly in the United States, European Union, and United Kingdom.
Financial Metrics and Material Changes
- Revenue, net income, operating profit, cash flow, margins, debt, liquidity, and other 2021 financial metrics are not provided in the filing text.
- Comparative changes versus 2020 are not provided.
- The filing does not provide a clear value for working capital, cash resources, or outstanding debt.
Guidance, Outlook, Risks, and Unusual Items
- Pharming targeted global regulatory filings for leniolisib, its oral PI3K delta inhibitor for activated PI3K delta syndrome, from the second quarter of 2022 onward. Leniolisib had met both primary endpoints in a registration-enabling Phase 2/3 study in the United States and Europe.
- The company is investigating RUCONEST in additional indications, including pre-eclampsia, acute kidney injury, and severe COVID-19 pneumonia.
- Pharming is collaborating with Orchard Therapeutics on OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for hereditary angioedema, and is developing next-generation protein replacement therapies, including a preclinical Pompe disease program.
- Forward-looking statements are subject to risks involving clinical-trial scope and costs, scientific, regulatory and technical developments, commercial prospects, COVID-19-related operating challenges, and projected working-capital requirements and cash resources.
- The March 17, 2022 results announcement was scheduled to be preliminary and unaudited; no unusual accounting items or contingencies are quantified in this notice.
Important Facts for Investors to Verify
- Verify the subsequently released audited or finalized 2021 revenue, profitability, cash flow, cash balance, debt, and liquidity figures.
- Assess RUCONEST sales performance and geographic trends versus 2020.
- Confirm the timing and regulatory status of leniolisib filings and any related commercial-readiness costs.
- Review clinical, regulatory, manufacturing, and funding risks affecting the pipeline and working-capital outlook.
- Read Pharming’s 2021 annual report and Form 20-F for detailed risk factors and financial disclosures.